Dyadic and Inzymes Set 2026 Launch for Non-Animal Dairy Enzyme After Development Milestone
Event summary
- Dyadic and Inzymes completed final development of recombinant non-animal bovine chymosin, a key cheese production enzyme.
- The milestone triggers a $200,000 payment to Dyadic and future royalty eligibility.
- Global dairy processing enzymes market valued at $1.5–$2.0 billion annually.
- Commercialization planned for 2026 under a 2023 collaboration agreement.
The big picture
This development underscores the growing demand for sustainable, fermentation-derived alternatives to animal-sourced enzymes in the dairy industry. The collaboration highlights Dyadic's ability to scale microbial expression platforms for commercial applications, positioning it in a market driven by increasing global cheese consumption and regulatory pressures for sustainable food production.
What we're watching
- Market Expansion
- How Dyadic will leverage this success to expand into additional enzyme and protein opportunities across its business segments.
- Execution Risk
- Whether the companies can maintain development momentum and meet the 2026 commercialization timeline.
- Competitive Positioning
- The pace at which Dyadic and Inzymes can differentiate their non-animal enzyme solutions in a growing sustainable food market.
Related topics